{"id":1832,"date":"2020-01-30T18:52:14","date_gmt":"2020-01-30T18:52:14","guid":{"rendered":"https:\/\/blogs.cooperhealth.org\/sjmedicalreport\/?p=1832"},"modified":"2020-01-30T19:25:15","modified_gmt":"2020-01-30T19:25:15","slug":"coopers-inflammatory-breast-cancer-program-specialized-resources-for-an-aggressive-disease","status":"publish","type":"post","link":"https:\/\/blogs.cooperhealth.org\/sjmedicalreport\/2020\/01\/30\/coopers-inflammatory-breast-cancer-program-specialized-resources-for-an-aggressive-disease\/","title":{"rendered":"Cooper\u2019s Inflammatory Breast Cancer Program: Specialized Resources for an Aggressive Disease"},"content":{"rendered":"
\"\"

\u201cUnfortunately, IBC presents similar to
mastitis, and a lot of women will see their
primary care physician with symptoms such
as skin redness, warmth and tenderness. The skin may also have a thick orange-peel look.” -Dr. Loveland-Jones<\/p><\/div>\n

\u201cIt\u2019s rapidly progressive and quite aggressive, and many women at the time of diagnosis already have lymph node involvement,\u201d says breast surgeon Catherine Loveland-Jones, MD<\/a>, associate director of the Janet Knowles Breast Cancer Center at MD Anderson Cancer Center at Cooper. \u201cTo stop it in its tracks, it\u2019s important to move quickly.\u201d<\/p>\n

\u201cIt\u201d is inflammatory breast cancer (IBC), a rare form of breast cancer that affects 0.5% to 2% of women. It disproportionately affects African American women, and they tend to be diagnosed at a younger age.<\/p>\n

\u201cUnfortunately, IBC presents similar to mastitis, and a lot of women will see their primary care physician with symptoms such as skin redness, warmth and tenderness,\u201d Dr. Loveland continues. The skin may also have a thick orange-peel look.<\/p>\n

\u201cWhile it\u2019s reasonable to do a brief course of antibiotic therapy, it\u2019s important to keep the possibility of IBC in mind,\u201d she advises. \u201cIf patients don\u2019t respond to a one-week course of antibiotics, the possibility of IBC grows stronger\u2014and the patient should be seen by a specialist as soon as possible.\u201d MD Anderson at Cooper has launched a multidisciplinary IBC program\u2014the only one of its kind in South Jersey\u2014to provide fast, specialized care for this aggressive cancer.<\/p>\n

\"Catherine

Catherine E Loveland-Jones, MD, MS<\/p><\/div>\n

\u201cGiven our patient population here in South Jersey, we are particularly\u00a0excited to offer this program,\u201d says MD Anderson at Cooper breast medical oncologist Kamel Abou Hussein, MD<\/a>. \u201cWe deal with IBC as an emergency; patients generally can be seen by our team within 24 to 48 hours.\u201d<\/p>\n

\u201cTreatment then usually begins with upfront systemic therapy,\u201d Dr. Abou Hussein explains. \u201cHistorically we\u2019ve used chemotherapy and sometimes add targeted therapy in combination, depending on what type of IBC we\u2019re dealing with\u2014 hormone receptor positive, triple negative or HER2-positive disease. If the cancer is locally advanced, this neoadjuvant treatment helps us get a good handle on the disease with the goal of reducing or even eliminating it. Then we move on to surgery.\u201d<\/p>\n

\u201cMastectomy is required, along with the removal of lymph nodes,\u201d Dr. Loveland-Jones says. \u201cThis is followed by radiation therapy, and we\u2019ll often do additional systemic therapy on the back end. It could include chemo, or anti-hormonal treatment, tailored to the biologic profile of the cancer.\u201d<\/p>\n

\"Kamel

Kamel Abou Hussein, MD<\/p><\/div>\n

Cooper\u2019s multidisciplinary IBC program provides streamlined access to all the specialty expertise a patient requires, including a breast surgeon, breast medical oncologist, radiation oncologist, genetic counselor and radiologist\u2014all in one place.<\/p>\n

\u201cIt\u2019s coordinated, timely care following the same practices and protocols at MD Anderson in Houston,\u201d Dr. Abou Hussein notes. \u201cWe also can give IBC patients access to clinical trials, knowing that the disease microenvironment and the potential targets are likely different for IBC compared to other types of breast cancer.\u201d In fact, Dr. Abou Hussein is the local principal investigator for a new study for patient with metastatic IBC.<\/p>\n

Both doctors acknowledge that the 5-year survival rate for IBC is poor, and the recurrence rate is high\u2014due, in part, to its aggressive nature\u2014and that the best way to optimize outcomes is to ensure patients receive the correct course of treatment, which includes systemic therapy, surgery, and radiation.<\/p>\n

\u201cBecause IBC is very fast growing, it\u2019s crucial that IBC be treated as quickly as possible and by specialized experts,\u201d says Dr. Hussein.<\/p>\n

\u201cEarly referral is key, and we\u2019re able to see patients without delay,\u201d Dr. Loveland-Jones adds.<\/p>\n

\n

Cooper\u2019s multidisciplinary IBC program provides streamlined access to all the specialty expertise a patient requires, including a breast surgeon, breast medical oncologist, radiation oncologist, genetic counselor and radiologist \u2014 all in one place. To discuss a patient or for a physician-to-physician referral, please call Dr. Loveland-Jones at 856.735.6207 or Dr. Abou Hussein at 856.735.6115.<\/p>\n","protected":false},"excerpt":{"rendered":"

\u201cIt\u2019s rapidly progressive and quite aggressive, and many women at the time of diagnosis already have lymph node involvement,\u201d says breast surgeon Catherine Loveland-Jones, MD, associate director of the Janet Knowles Breast Cancer Center at MD Anderson Cancer Center at Cooper. \u201cTo stop it in its tracks, it\u2019s important to move quickly.\u201d \u201cIt\u201d is inflammatory … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":7,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[3,169],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-rmineo","4":"post-1832","6":"format-standard","7":"category-featured","8":"category-patient-programs"},"_links":{"self":[{"href":"https:\/\/blogs.cooperhealth.org\/sjmedicalreport\/wp-json\/wp\/v2\/posts\/1832","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/blogs.cooperhealth.org\/sjmedicalreport\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/blogs.cooperhealth.org\/sjmedicalreport\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/blogs.cooperhealth.org\/sjmedicalreport\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/blogs.cooperhealth.org\/sjmedicalreport\/wp-json\/wp\/v2\/comments?post=1832"}],"version-history":[{"count":5,"href":"https:\/\/blogs.cooperhealth.org\/sjmedicalreport\/wp-json\/wp\/v2\/posts\/1832\/revisions"}],"predecessor-version":[{"id":1841,"href":"https:\/\/blogs.cooperhealth.org\/sjmedicalreport\/wp-json\/wp\/v2\/posts\/1832\/revisions\/1841"}],"wp:attachment":[{"href":"https:\/\/blogs.cooperhealth.org\/sjmedicalreport\/wp-json\/wp\/v2\/media?parent=1832"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/blogs.cooperhealth.org\/sjmedicalreport\/wp-json\/wp\/v2\/categories?post=1832"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/blogs.cooperhealth.org\/sjmedicalreport\/wp-json\/wp\/v2\/tags?post=1832"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}